Creative Medical Technology (NASDAQ:CELZ) Shares Down 8.9% – What’s Next?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ)’s share price fell 8.9% on Monday . The stock traded as low as $2.02 and last traded at $2.05. 133,111 shares traded hands during mid-day trading, an increase of 20% from the average session volume of 111,347 shares. The stock had previously closed at $2.25.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wall Street Zen cut Creative Medical Technology from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Creative Medical Technology in a report on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.

Creative Medical Technology Stock Performance

The business has a 50-day simple moving average of $2.44 and a 200-day simple moving average of $2.96. The company has a market cap of $5.29 million, a price-to-earnings ratio of -0.70 and a beta of 2.08.

Creative Medical Technology (NASDAQ:CELZ) last released its earnings results on Friday, November 7th. The company reported ($0.48) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.48). Research analysts anticipate that Creative Medical Technology Holdings, Inc. will post -3.19 EPS for the current year.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.